Search Results 1951-1960 of 17179 for Osteoarthritis

  1. Thomas C. Spelsberg, Ph.D. - Mayo Clinic Faculty Profiles

    D., is engaged in studies regarding the mechanism of action of estrogens, selective estrogen receptor modulators (SERMs), select growth factors, and ...

  2. Dan Dragomir-Daescu, Ph.D. - Mayo Clinic Faculty Profiles

    Biomedical engineering researcher Dan Dragomir-Daescu, Ph.D., designs and tests cardiovascular devices such as stent-grafts and studies vascular ...

  3. Publications - Fergus J. Couch, Ph.D. - Mayo Clinic

    Premji SK, Ruddy KJ, Vierkant RA, Larson N, Loprinzi C, Dulmage B, Lustberg M, Couch FJ, Olson JE, Cathcart-Rake E. Perceptions of Delayed Alopecia Among ...

  4. Hyperoxaluria And Oxalosis Clinical Trials - Mayo Clinic Research

    The purpose of the study is to determine if the investigational medicine, lumasiran, is able to reduce the production of oxalate in the liver and to evaluate ...

  5. Audiology - Conditions treated - Mayo Clinic

    Mayo Clinic ear, nose and throat (ENT)/head and neck specialists treat medical conditions that cause hearing loss, dizziness or imbalance and offer a full range ...

  6. Mayo Clinic Minute: Help with kyphosis, or roundback

    One type of kyphosis, called Scheuermann's disease, is the most common, requiring attention of a medical professional. Learn more.

  7. POEMS syndrome - Care at Mayo Clinic

    POEMS syndrome — Learn about diagnosis and treatment options at Mayo Clinic for this rare blood disorder that affects many parts of the body.

  8. Publications - Thomas M. Habermann, M.D. - Mayo Clinic

    Atallah-Yunes SA, Habermann TM, Khurana A. Targeted therapy in Burkitt lymphoma: Small molecule inhibitors under investigation. Br J Haematol. 2024 Jun; 204(6): ...

  9. Epigenetic Etiology of Human Disease: Keith D. Robertson

    Dr. Robertson's Epigenetic Etiology of Human Disease Lab at Mayo Clinic studies DNA methylation and hydroxymethylation in health and disease.

  10. A Study to Evaluate MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients with Amyotrophic Lateral Sclerosis (ALS) - Mayo Clinic

    Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...